| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.
|
J Clin Oncol
|
2002
|
3.49
|
|
2
|
Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
|
Strahlenther Onkol
|
2008
|
2.02
|
|
3
|
Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.70
|
|
4
|
Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
|
J Clin Oncol
|
2006
|
1.53
|
|
5
|
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
|
J Clin Oncol
|
2008
|
1.35
|
|
6
|
DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis.
|
Strahlenther Onkol
|
2010
|
1.21
|
|
7
|
DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer.
|
Strahlenther Onkol
|
2014
|
1.12
|
|
8
|
DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC).
|
Strahlenther Onkol
|
2009
|
1.10
|
|
9
|
Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer : beware of one-stop shops?
|
Strahlenther Onkol
|
2010
|
1.06
|
|
10
|
DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy.
|
Strahlenther Onkol
|
2007
|
1.05
|
|
11
|
[Long-term results following multidisciplinary treatment of localized Ewing's sarcoma in children and adolescents].
|
Strahlenther Onkol
|
2008
|
1.05
|
|
12
|
Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.05
|
|
13
|
Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial.
|
Strahlenther Onkol
|
2008
|
1.04
|
|
14
|
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.03
|
|
15
|
Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.
|
BMC Cancer
|
2006
|
1.01
|
|
16
|
DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease.
|
Strahlenther Onkol
|
2008
|
0.99
|
|
17
|
Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.96
|
|
18
|
Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.95
|
|
19
|
Radiogenic lymphangiogenesis in the skin.
|
Am J Pathol
|
2007
|
0.95
|
|
20
|
Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01).
|
Strahlenther Onkol
|
2014
|
0.91
|
|
21
|
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
|
Radiat Oncol
|
2013
|
0.91
|
|
22
|
Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.91
|
|
23
|
Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
|
Strahlenther Onkol
|
2008
|
0.88
|
|
24
|
Hemithorax irradiation for Ewing tumors of the chest wall.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.87
|
|
25
|
DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.
|
Strahlenther Onkol
|
2015
|
0.85
|
|
26
|
Cancer-related anemia: biological findings, clinical implications and impact on quality of life.
|
Oncology
|
2005
|
0.85
|
|
27
|
Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line.
|
Oncol Rep
|
2005
|
0.84
|
|
28
|
Radiotherapy in multilocalized lymphedema-associated angiosarcoma.
|
Eur J Dermatol
|
2005
|
0.83
|
|
29
|
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
|
Radiat Oncol
|
2012
|
0.82
|
|
30
|
The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT/HIF-1β) is influenced by hypoxia and hypoxia-mimetics.
|
Cell Physiol Biochem
|
2013
|
0.82
|
|
31
|
Inverse treatment planning for spinal robotic radiosurgery: an international multi-institutional benchmark trial.
|
J Appl Clin Med Phys
|
2016
|
0.81
|
|
32
|
Stabilisation and knockdown of HIF--two distinct ways comparably important in radiotherapy.
|
Cell Physiol Biochem
|
2011
|
0.81
|
|
33
|
Oxygenation measurements in head and neck cancers during hyperbaric oxygenation.
|
Strahlenther Onkol
|
2002
|
0.81
|
|
34
|
[Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study].
|
Strahlenther Onkol
|
2002
|
0.80
|
|
35
|
Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy.
|
Gynecol Oncol
|
2006
|
0.80
|
|
36
|
[Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
|
Strahlenther Onkol
|
2005
|
0.80
|
|
37
|
Accelerated partial-breast irradiation (APBI)--ready for prime time?
|
Strahlenther Onkol
|
2009
|
0.79
|
|
38
|
Radioprotective effects of amifostine in vitro and in vivo measured with the comet assay.
|
Strahlenther Onkol
|
2004
|
0.79
|
|
39
|
Factors influencing heterogeneity of radiation-induced DNA-damage measured by the alkaline comet assay.
|
Radiat Oncol
|
2012
|
0.79
|
|
40
|
Erythropoietin and radiotherapy: a dangerous combination?
|
Strahlenther Onkol
|
2004
|
0.79
|
|
41
|
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
|
Strahlenther Onkol
|
2003
|
0.78
|
|
42
|
A liquid fluorescence dosimeter for proton dosimetry.
|
Phys Med Biol
|
2012
|
0.78
|
|
43
|
[Extranodal non-Hodgkin's lymphoma of MALT-type stage I. A case report].
|
Strahlenther Onkol
|
2003
|
0.78
|
|
44
|
Mitochondrial OXPHOS functions in R1H rhabdomyosarcoma and skeletal muscles of the rat.
|
Neurochem Res
|
2007
|
0.77
|
|
45
|
Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.77
|
|
46
|
Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
|
Strahlenther Onkol
|
2003
|
0.77
|
|
47
|
Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer.
|
Anticancer Drugs
|
2002
|
0.77
|
|
48
|
DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices.
|
Strahlenther Onkol
|
2015
|
0.77
|
|
49
|
The prognostic value of tumor necrosis in patients undergoing stereotactic radiosurgery of brain metastases.
|
Radiat Oncol
|
2013
|
0.77
|
|
50
|
Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
|
Ann Surg Oncol
|
2013
|
0.77
|
|
51
|
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
|
Strahlenther Onkol
|
2007
|
0.76
|
|
52
|
[Whole-breast irradiation following breast-conserving surgery of ductal carcinomain situ is indispensable. Update of the 2005 DEGRO (German Society of Radiation Oncology) Guideline on Radiation Therapy for Breast Cancer].
|
Strahlenther Onkol
|
2006
|
0.76
|
|
53
|
[Prognostic factors after surgery and adjuvant radiotherapy in cervical cancers. A retrospective analysis of 298 patients after surgery and adjuvant radiotherapy].
|
Strahlenther Onkol
|
2005
|
0.75
|
|
54
|
[Patients with "extensive disease" form of small cell bronchial carcinoma also benefit from consolidating mediastinal irradiation similarly to the procedure used in "limited disease"].
|
Strahlenther Onkol
|
2015
|
0.75
|
|
55
|
[No increased rate of secondary malignancies after pelvic radiotherapy].
|
Strahlenther Onkol
|
2015
|
0.75
|
|
56
|
[Subclinical heart damage caused by adjuvant anthracycline chemotherapy].
|
Strahlenther Onkol
|
2002
|
0.75
|
|
57
|
[Role of radiation therapy on the use of primary ("neoadjuvant") systemic treatment of breast cancer].
|
Strahlenther Onkol
|
2006
|
0.75
|
|
58
|
Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
|
Onkologie
|
2005
|
0.75
|
|
59
|
Survival of patients in clinical stages I-IIIb of non-small-cell lung cancer treated with radiation therapy alone. Results of a population-based study in Southern Saxony-Anhalt.
|
Strahlenther Onkol
|
2004
|
0.75
|
|
60
|
Radiosensitization of a human soft tissue sarcoma cell line US8-93 (mt-p53) with the oxidizer sodium peroxodisulfate.
|
Oncol Rep
|
2004
|
0.75
|